Quantum Leap Healthcare Collaborative
search

Recent Results & Agents

Widely hailed as the future of phase II drug development, the adaptive I-SPY2 platform trial has set a new benchmark for efficiency, through innovation in trial design and clinical operations.

I-SPY 2 Agent Timeline

The I-SPY 2 TRIAL's ground-breaking adaptive, multi-agent design allows up to five agents (or combinations of agents) to be evaluated in parallel. Click on an agent of interest to view more information about the agent and the results from I-SPY 2.
PEMBROLIZUMAB x 8 SGN-LIV1A DURVALUMAB + OLAPARIB TUCATINIB SD-101 + PEMBROLIZUMAB CEMIPLIMAB CEMIPLIMAB + REGN3767 SYD985 TRILACICLIB ± TRASTUZUMAB DOSTARLIMAB + ORAL PACLITAXEL/ENCEQUIDAR ± CARBO Graduated Completed In Progress Planned Halted
PERTUZUMAB TDM1 + PERTUZUMAB GANETESPIB PLX3397 PEMBROLIZUMAB x 4 TALAZOPARIB + IRINOTECAN PATRITUMAB
2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 CONTROL NERATINIB VELIPARIB + CARBOPLATIN AMG 386 GANITUMAB MK2206

I-SPY2 Agents

The I-SPY2 Trial's ground-breaking adaptive, multi-agent design allows up to five agents (or combinations of agents) to be evaluated in parallel. Click on an agent of interest to view more information about the agent and the results obtained in I-SPY. Agents in the table below are ordered newest to oldest beast upon date of entry into the study.
Agent(s)
Status
Currently Enrolling
Currently Enrolling
Currently Enrolling
Currently Enrolling
Currently Enrolling
Currently Enrolling
Completed (Results Pending)
Completed (Results Pending)
Graduated
Halted for Toxicity
Stopped for Futility
Graduated
Graduated
Stopped for Futility
Stopped for Futility
Graduated
Graduated